Inhibitory effects of B‑cell translocation gene 2 on skin cancer cells via the Wnt/β‑catenin signaling pathway

Gao,Shou‑Song; Yang,Xiao‑Hong; Wang,Meng

doi:10.3892/mmr.2016.5596

Inhibitory effects of B‑cell translocation gene 2 on skin cancer cells via the Wnt/β‑catenin signaling pathway

Authors:
- Shou‑Song Gao
- Xiao‑Hong Yang
- Meng Wang
View Affiliations

Affiliations: Department of Cosmetic Surgery, Hangzhou Yue‑ke Medical Cosmetology Clinic, Hangzhou, Zhejiang 310000, P.R. China, Department of Dermatology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310000, P.R. China
Published online on: August 8, 2016 https://doi.org/10.3892/mmr.2016.5596
Pages: 3464-3468

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

B-cell translocation gene 2 (BTG2), a tumor suppressor gene, is downregulated in several types of human cancer cell. However, its function in skin cancer cells has not been fully elucidated. Therefore, the present study investigated the expression and function of BTG2 in skin cancer cells, and investigated the underlying molecular mechanism. The results indicated that BTG2 expression was downregulated in skin cancer cell lines. Overexpression of BTG2 significantly inhibited cell proliferation, cell cycle progression, and the invasion and migration of skin cancer cells. Furthermore, it was determined that overexpression of BTG2 significantly decreased the protein expression levels of β‑catenin, cyclin D1 and v‑myc avian myelocytomatosis viral oncogene homolog in skin cancer cells. This suggests that BTG2 may function as a tumor suppressor by interfering with the Wnt/β‑catenin signaling pathway in skin cancer cells. Thus, novel therapeutic strategies and agents targeting BTG2 may be potential treatments for skin cancer.

View Figures

View References

1	Kumar A, Shrestha PR, Pun J, Thapa P, Manandhar M and Sathian B: Profile of skin biopsies and patterns of skin cancer in a tertiary care center of Western Nepal. Asian Pac J Cancer Prev. 16:3403–3406. 2015. View Article : Google Scholar : PubMed/NCBI
2	Jiang YJ and Bikle DD: LncRNA: A new player in 1α, 25(OH)(2) vitamin D(3)/VDR protection against skin cancer formation. Exp Dermatol. 23:147–150. 2014. View Article : Google Scholar : PubMed/NCBI
3	Singh T and Katiyar SK: Green tea polyphenol, (-)-epigallocatechin-3-gallate, induces toxicity in human skin cancer cells by targeting β-catenin signaling. Toxicol Appl Pharmacol. 273:418–424. 2013. View Article : Google Scholar : PubMed/NCBI
4	Ikematsu N, Yoshida Y, Kawamura-Tsuzuku J, Ohsugi M, Onda M, Hirai M, Fujimoto J and Yamamoto T: Tob2, a novel anti-proliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin-dependent kinases. Oncogene. 18:7432–7441. 1999. View Article : Google Scholar : PubMed/NCBI
5	Buanne P, Corrente G, Micheli L, Palena A, Lavia P, Spadafora C, Lakshmana MK, Rinaldi A, Banfi S, Quarto M, et al: Cloning of PC3B, a novel member of the PC3/BTG/TOB family of growth inhibitory genes, highly expressed in the olfactory epithelium. Genomics. 68:253–263. 2000. View Article : Google Scholar : PubMed/NCBI
6	Lim IK: TIS21 (/BTG2/PC3) as a link between ageing and cancer: Cell cycle regulator and endogenous cell death molecule. J Cancer Res Clin Oncol. 132:417–426. 2006. View Article : Google Scholar : PubMed/NCBI
7	Winkler GS: The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol. 222:66–72. 2010. View Article : Google Scholar
8	Duriez C, Moyret-Lalle C, Falette N, El-Ghissassi F and Puisieux A: BTG2, its family and its tutor. Bull Cancer. 91:E242–E253. 2004.PubMed/NCBI
9	Zhang Y-J, Wei L, Liu M, Li J, Zheng Y-Q, Gao Y and Li X-R: BTG2 inhibits the proliferation, invasion, and apoptosis of MDA-MB-231 triple-negative breast cancer cells. Tumor Biol. 34:1605–1613. 2013. View Article : Google Scholar
10	Devanand P, Kim SI, Choi YW, Sheen SS, Yim H, Ryu MS, Kim SJ, Kim WJ and Lim IK: Inhibition of bladder cancer invasion by Sp1-mediated BTG2 expression via inhibition of DNA methyltransferase 1. FEBS J. 281:5581–5601. 2014. View Article : Google Scholar : PubMed/NCBI
11	el-Ghissassi F, Valsesia-Wittmann S, Falette N, Duriez C, Walden PD and Puisieux A: BTG2 (TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells. Oncogene. 21:6772–6778. 2002. View Article : Google Scholar : PubMed/NCBI
12	Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR and Gudkov AV: A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev. 20:236–252. 2006. View Article : Google Scholar : PubMed/NCBI
13	Lim YB, Park TJ and Lim IK: B cell translocation gene 2 enhances susceptibility of HeLa cells to doxorubicin-induced oxidative damage. J Biol Chem. 283:33110–33118. 2008. View Article : Google Scholar : PubMed/NCBI
14	Zhang L, Huang H, Wu K, Wang M and Wu B: Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro. Mol Biol Rep. 37:2579–2586. 2010. View Article : Google Scholar
15	Möllerström E, Kovács A, Lövgren K, Nemes S, Delle U, Danielsson A, Parris T, Brennan DJ, Jirström K, Karlsson P and Helou K: Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray. BMC Cancer. 10:2962010. View Article : Google Scholar : PubMed/NCBI
16	Li J, Ji L, Chen J, Zhang W and Ye Z: Wnt/β-catenin signaling pathway in skin carcinogenesis and therapy. Biomed Res Int. 2015:9648492015.
17	Kuphal S and Bosserhoff AK: Phosphorylation of β-catenin results in lack of β-catenin signaling in melanoma. Int J Oncol. 39:235–243. 2011.PubMed/NCBI
18	Kang MI, Baker AR, Dextras CR, Cabarcas SM, Young MR and Colburn NH: Targeting of noncanonical Wnt5a signaling by AP-1 blocker dominant-negative Jun when it inhibits skin carcinogenesis. Genes Cancer. 3:37–50. 2012. View Article : Google Scholar : PubMed/NCBI
19	Bhatia N and Spiegelman VS: Activation of Wnt/beta-catenin/Tcf signaling in mouse skin carcinogenesis. Mol Carcinog. 42:213–221. 2005. View Article : Google Scholar : PubMed/NCBI
20	Zhang Z, Chen C, Wang G, Yang Z, San J, Zheng J, Li Q, Luo X, Hu Q, Li Z and Wang D: Aberrant expression of the p53-inducible antiproliferative gene BTG2 in hepatocellular carcinoma is associated with overexpression of the cell cycle-related proteins. Cell Biochem Biophys. 61:83–91. 2011. View Article : Google Scholar : PubMed/NCBI
21	Horvilleur E, Bauer M, Goldschneider D, Mergui X, de la Motte A, Bénard J, Douc-Rasy S and Cappellen D: p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells. Nucleic Acids Res. 36:4222–4232. 2008. View Article : Google Scholar : PubMed/NCBI
22	Yang CH, Yue J, Pfeffer SR, Handorf CR and Pfeffer LM: MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem. 286:39172–39178. 2011. View Article : Google Scholar : PubMed/NCBI
23	Takahashi F, Chiba N, Tajima K, Hayashida T, Shimada T, Takahashi M, Moriyama H, Brachtel E, Edelman E, Ramaswamy S and Maheswaran S: Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. Oncogene. 30:3084–3095. 2011. View Article : Google Scholar : PubMed/NCBI
24	Segev DL, Kucirka LM, Oberai PC, Parekh RS, Boulware LE, Powe NR and Montgomery RA: Age and comorbidities are effect modifiers of gender disparities in renal transplantation. J Am Soc Nephrol. 20:621–628. 2009. View Article : Google Scholar : PubMed/NCBI
25	Liu M, Wu H, Liu T, Li Y, Wang F, Wan H, Li X and Tang H: Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res. 19:828–837. 2009. View Article : Google Scholar : PubMed/NCBI
26	Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, García JJ and Kolch W: Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res. 11:7392–7397. 2005. View Article : Google Scholar : PubMed/NCBI
27	Kawakubo H, Brachtel E, Hayashida T, Yeo G, Kish J, Muzikansky A, Walden PD and Maheswaran S: Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res. 66:7075–7082. 2006. View Article : Google Scholar : PubMed/NCBI
28	Saito-Diaz K, Chen TW, Wang X, Thorne CA, Wallace HA, Page-McCaw A and Lee E: The way Wnt works: Components and mechanism. Growth Factors. 31:1–31. 2013. View Article : Google Scholar :
29	MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
30	Wang J, Wang X, Gong W, Mi B, Liu S and Jiang B: Increased expression of beta-catenin, phosphorylated glycogen synthase kinase 3beta, cyclin D1, and c-myc in laterally spreading colorectal tumors. J Histochem Cytochem. 57:363–371. 2009. View Article : Google Scholar :
31	Ripple MJ, Parker Struckhoff A, Trillo-Tinoco J, Li L, Margolin DA, McGoey R and Del Valle L: Activation of c-Myc and Cyclin D1 by JCV T-Antigen and β-catenin in Colon Cancer. PLoS One. 9:e1062572014. View Article : Google Scholar
32	Baldin V, Lukas J, Marcote M, Pagano M and Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
33	Dang CV: c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 19:1–11. 1999. View Article : Google Scholar